Video

Institutional Perspectives in Cancer: Melanoma - Chaired by Carlo Contreras, MD

Institutional Perspectives in Cancer: Melanoma - Chaired by Carlo Contreras, MD

The live filming of this virtual event in our IPC series is now on-demand.

OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer management. Attendees will not only improve their knowledge of novel treatment approaches, but also leave the event the with confidence and intent to apply state-of-the-art treatment strategies to care for their patients. Each event is dedicated to the latest research in one of the following therapeutic areas: Breast Cancer, Lung Cancer, GU & Prostate Cancer, Hematology, or Melanoma.

The State of the Science Summits and IPC assemble academic and community-based physicians & healthcare professionals across key disciplines from medical and surgical oncology. Specialist experts serve as faculty for these premier and renowned oncology summits, which focus on the most relevant cancer topics to ultimately improve patient care.

Speakers 

  1. Claire Verschraegen, MS, MD, FACP | The Ohio State University Comprehensive Cancer Center
  2. Richard Wu, MD, PhD | The Ohio State University Comprehensive Cancer Center
  3. Carlo Contreras, MD | The Ohio State University Comprehensive Cancer Center
  4. Kari Kendra, MD, PhD | The Ohio State University Comprehensive Cancer Center

Topics

  1. Sequencing in Melanoma
  2. Importance of BRAFV600
  3. CSCC and BCC Treatment Updates
  4. SWOG 1512: Neoadjuvant immunotherapy for desmoplastic melanoma

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
David M. O’Malley, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
 Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases